Dosagens séricas de proteína C-reativa na fase inicial da sepse abdominal e pulmonar

Orati, Juliane Agustini; Almeida, Patricia; Santos, Vanessa; Ciorla, Gustavo; Lobo, Suzana Margareth

doi:10.1590/s0103-507x2013000100003

Cited by 9 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 Numerous studies have reported the high sensitivity and specificity of CRP for the diagnosis of sepsis. 21 – 23 In ICU patients, elevated concentrations of serum CRP upon admission are correlated with an increased risk of organ failure and death. 24 However, other studies have demonstrated that CRP levels are not indicative of survival in sepsis patients.…”

Section: Proinflammatory Biomarkersmentioning

confidence: 99%

Biomarkers for Sepsis: What is and What Might Be?

2015

View full text Add to dashboard Cite

Every year numerous individuals develop the morbid condition of sepsis. Therefore, novel biomarkers that might better inform clinicians treating such patients are sorely needed. Difficulty in identifying such markers is in part due to the complex heterogeneity of sepsis, resulting from the broad and vague definition of this state/condition based on numerous possible clinical signs and symptoms as well as an incomplete understanding of the underlying pathobiology of this complex condition. This review considers some of the attempts that have been made so far, looking at both the pro- and anti-inflammatory response to sepsis, as well as genomic analysis, as sources of potential biomarkers. Irrespective, for functional biomarker(s) of sepsis to successfully translate from the laboratory to a clinical setting, the biomarker must be target specific and sensitive as well as easy to implement/interpret, and be cost effective, such that they can be utilized routinely in patient diagnosis and treatment.

show abstract

Section: Proinflammatory Biomarkersmentioning

confidence: 99%

Biomarkers for Sepsis: What is and What Might Be?

2015

View full text Add to dashboard Cite

show abstract

“… 33 Patients with abdominal sepsis had higher CRP than those with pulmonary sepsis (mean 178 versus 149 mg/L) (Brazil). 34 …”

Section: Resultsmentioning

confidence: 99%

C-reactive protein and procalcitonin use in adults in low- and middle-income countries: a narrative review

Lamrous

Repetto

Depp

et al. 2023

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Objectives C-reactive protein (CRP) and procalcitonin (PCT) are widely used biomarkers in high-income countries. However, evidence for their use in low- and middle-income countries (LMICs) is scant. Because many factors, including rates of endemic disease, comorbidities and genetics, may influence biomarkers’ behaviour, we aimed to review available evidence generated in LMICs. Methods We searched the PubMed database for relevant studies within the last 20 years that originated in regions of interest (Africa, Latin America, Middle East, South Asia or South East Asia), and full-text articles involving diagnosis, prognostication and evaluation of therapeutic response with CRP and/or PCT in adults (n = 88) were reviewed and categorized in 12 predefined focus areas. Results Overall, results were highly heterogeneous, at times conflicting, and often lacking clinically useful cut-off values. However, most studies demonstrated higher levels of CRP/PCT in patients with bacterial versus other infections. HIV and TB patients had consistently higher levels of CRP/PCT versus controls. In addition, higher CRP/PCT levels at baseline and follow-up in HIV, TB, sepsis and respiratory tract infections were associated with poorer prognosis. Conclusions Evidence generated from LMIC cohorts suggests that CRP and PCT may have potential to become effective clinical guiding tools particularly in respiratory tract infections, sepsis and HIV/TB. However, more studies are needed to define potential scenarios for use and cost-effectiveness. Consensus across stakeholders regarding target conditions, laboratory standards and cut-off values would support the quality and applicability of future evidence.

show abstract

“…The role of conventional inflammatory biomarkers (CRP and PCT) in the diagnosis of sepsis/septic shock and the prediction of prognosis is controversial [ 16 , 17 , 18 , 19 , 20 ]. Also, these biomarkers are mostly increased in severe bacterial infections, but their late rise, elevation during some viral infections, and the requirement for serial measurement limit their use in the ED for the differential diagnosis and prognosis of sepsis and septic shock [ 20 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Early Indicator of Mortality in Pediatric Septic Shock

Turan,

Yurtseven,

Ozkaya

et al. 2024

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundDespite advancements in antibiotic therapy and resuscitation protocols, sepsis and septic shock remain major contributors to morbidity and mortality in children. We aimed to investigate the utility of soluble urokinase plasminogen activator receptor (suPAR) for the early detection of septic shock and to evaluate its accuracy in predicting mortality.MethodsA prospective study was conducted in a tertiary pediatric emergency department (ED), enrolling patients diagnosed with the sepsis, severe sepsis, or septic shock. In addition to assessing infection biomarkers such as C‐reactive protein and procalcitonin, suPAR levels were quantified upon admission using enzyme‐linked immunosorbent assay. The primary outcome measure was 30‐day mortality.ResultsOverall 72 patients and 80 healthy children included. Plasma suPAR levels demonstrated a statistically significant elevation in the sepsis, severe sepsis, and septic shock groups compared with the control group (p < 0.001 for all). The septic shock group exhibited the highest suPAR levels upon admission, surpassing both the sepsis and severe sepsis groups (p = 0.009 and 0.042). ROC analysis underscored the promising potential of suPAR with an AUC of 0.832 for septic shock. Analysis of mortality prediction revealed significantly higher suPAR levels in nonsurvivors than survivors (9.7 ng/mL vs. 4.2 ng/mL; p < 0.001). Employing plasma suPAR levels to discriminate between mortality and survival, a threshold of ≥7.0 ng/mL demonstrated a sensitivity of 90.9% and specificity of 71.0%.ConclusionPlasma suPAR levels have the potential as a biomarker for predicting mortality in children with septic shock. In pediatric septic shock, the presence of plasma suPAR ≥7 ng/mL along with an underlying disease significantly increases the risk of mortality.

show abstract

Dosagens séricas de proteína C-reativa na fase inicial da sepse abdominal e pulmonar

Cited by 9 publications

References 32 publications

Biomarkers for Sepsis: What is and What Might Be?

Biomarkers for Sepsis: What is and What Might Be?

C-reactive protein and procalcitonin use in adults in low- and middle-income countries: a narrative review

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Early Indicator of Mortality in Pediatric Septic Shock

Contact Info

Product

Resources

About